Bulletin du cancer · 2026
[Effects of phytoestrogens on prognosis and hormonal markers of breast cancer: A systematic review of randomized controlled trials].
Аннотация на английскомСтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Poirier Laurence, Diorio Caroline
Аннотация
INTRODUCTION: Estrogen exposure is a known risk factor for breast cancer. Phytoestrogens, plant-derived compounds found in the diet, have a structure similar to estradiol. Observational studies suggest that they are associated with a reduced risk of breast cancer recurrence. The objective of this systematic review is to evaluate, based on data from randomized controlled trials, the effect of phytoestrogens on breast cancer prognosis and hormonal markers.
METHODS: MEDLINE, EMBASE, CENTRAL, and ClinicalTrials.gov were searched from inception to February 2026, without language restrictions. Randomized controlled trials assessing the effect of phytoestrogens on breast cancer prognosis (recurrence and mortality) or on circulating estrogen concentrations (estradiol and estrone) were included. Risk of bias was assessed using the Cochrane RoB-2 tool. A qualitative synthesis was conducted due to study heterogeneity.
RESULTS: Four trials (1698 patients) were included. One trial (1542 patients) reported a non-significant reduction in recurrence risk (Relative risk 0.97; 95% Confidence Interval [CI] 0.75-1.27). No randomized trial evaluated mortality. Three trials (156 patients) reported non-significant decreases in estradiol concentrations. One trial (19 patients) showed a significant reduction in estrone concentration (Mean difference -5.50pmol/L; 95% CI -7.53 to -3.47).
DISCUSSION: Overall, the available data from trials remain limited and do not provide sufficient support for a protective effect. However, the trials did not report any increase in recurrence risk (1 trial) or circulating estrogen levels (3 trials), rather they suggested trends toward reduction. These findings should nevertheless be interpreted with caution given the limited number of studies available and their relatively small sample sizes.
METHODS: MEDLINE, EMBASE, CENTRAL, and ClinicalTrials.gov were searched from inception to February 2026, without language restrictions. Randomized controlled trials assessing the effect of phytoestrogens on breast cancer prognosis (recurrence and mortality) or on circulating estrogen concentrations (estradiol and estrone) were included. Risk of bias was assessed using the Cochrane RoB-2 tool. A qualitative synthesis was conducted due to study heterogeneity.
RESULTS: Four trials (1698 patients) were included. One trial (1542 patients) reported a non-significant reduction in recurrence risk (Relative risk 0.97; 95% Confidence Interval [CI] 0.75-1.27). No randomized trial evaluated mortality. Three trials (156 patients) reported non-significant decreases in estradiol concentrations. One trial (19 patients) showed a significant reduction in estrone concentration (Mean difference -5.50pmol/L; 95% CI -7.53 to -3.47).
DISCUSSION: Overall, the available data from trials remain limited and do not provide sufficient support for a protective effect. However, the trials did not report any increase in recurrence risk (1 trial) or circulating estrogen levels (3 trials), rather they suggested trends toward reduction. These findings should nevertheless be interpreted with caution given the limited number of studies available and their relatively small sample sizes.